Title : Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review.

Pub. Date : 2016 Aug

PMID : 27376688






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Triple therapy with Pegylated-Interferon alpha (PEG-IFNalpha)/Ribavirin (RBV) and Boceprevir (Boc) or Telaprevir (Tel) significantly improved sustained virological response (SVR) rates for patients with genotype 1 HCV infection compared to PEG-IFNalpha/RBV alone (dual therapy). Ribavirin interferon alpha 1 Homo sapiens
2 BACKGROUND: Triple therapy with Pegylated-Interferon alpha (PEG-IFNalpha)/Ribavirin (RBV) and Boceprevir (Boc) or Telaprevir (Tel) significantly improved sustained virological response (SVR) rates for patients with genotype 1 HCV infection compared to PEG-IFNalpha/RBV alone (dual therapy). Ribavirin interferon alpha 1 Homo sapiens